Tumor Blood Testing Market Report 2026

Tumor Blood Testing Market Overview

• Tumor Blood Testing market size has reached to $5.98 billion in 2025 • Expected to grow to $11.13 billion in 2030 at a compound annual growth rate (CAGR) of 13.2% • Growth Driver: Rise In Cancer Prevalence Driving The Growth Of The Market Due To Increasing Demand For Early Detection And Improved Patient Outcomes • Market Trend: Focus On Non-Invasive Liquid Biopsy Technologies Driving Innovation And Efficiency In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tumor Blood Testing Market?

Tumor blood testing is a diagnostic technique that examines a blood sample to identify cancer-related biomarkers. It primarily detects genetic material released by tumors, such as circulating tumor DNA (ctDNA), providing a minimally invasive alternative to traditional tissue biopsies for cancer detection and monitoring. This method enables earlier diagnosis, continuous disease monitoring, and more informed treatment decisions. The main types of tests in the tumor blood testing market are circulating tumor cells (CTC) tests, circulating tumor DNA (CtDNA) tests, exosome-based tests, and others. Circulating tumor cells (CTC) tests refer to diagnostic tests that detect and analyze cancer cells that have detached from a primary tumor and are circulating in the bloodstream. The various technologies include polymerase chain reaction (PCR)-based testing, next-generation sequencing, microarray-based testing, mass spectrometry and immunoassays. The various types of cancers tested are breast cancer, colorectal cancer, lung cancer, prostate cancer, and melanoma. The key applications include early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The primary end users are hospitals, diagnostic laboratories, research institutes, and others.

What Is The Tumor Blood Testing Market Growth Forecast?

The tumor blood testing market size is expected to see rapid growth in the next few years. It will grow to $11.13 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to early cancer screening programs, ai-enabled genomic analysis, personalized medicine growth, expansion of companion diagnostics, clinical trial adoption. Major trends in the forecast period include liquid biopsy adoption, multi-cancer early detection, minimal residual disease monitoring, personalized oncology testing, high-sensitivity biomarker detection.

Global Tumor Blood Testing Market Segmentation

1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types 2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays 3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma 4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring 5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users Subsegments: 1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells 2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA 3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes 4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests

What Is The Driver Of The Tumor Blood Testing Market?

The increasing prevalence of cancer is expected to drive the growth of the tumor blood testing market in the coming years. Aging populations and exposure to risk factors such as poor diet, smoking, and pollution are contributing to a higher incidence of cancer, fueling demand for early detection methods. Tumor blood testing provides a minimally invasive approach to detect cancer before symptoms appear by identifying biomarkers in the bloodstream. This enables timely diagnosis, early treatment, improved patient outcomes, and ongoing monitoring of disease progression and therapy effectiveness. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, as of January 2022, the United States had an estimated 18.1 million cancer survivors, with projections expected to reach 26 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the tumor blood testing industry.

Key Players In The Global Tumor Blood Testing Market

Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

Global Tumor Blood Testing Market Trends and Insights

Major companies operating in the tumor blood testing market are focusing on developing innovative technology such as, non-invasive liquid biopsy technologies to enable early cancer detection, monitor treatment response, and assess disease progression more efficiently. Non-invasive liquid biopsy technologies are diagnostic tests that detect and analyze cancer-related biomarkers from bodily fluids, providing a safer and more convenient alternative to traditional tissue biopsies. For instance, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, launched the DELFI-Tumor Fraction (DELFI-TF) assay, a cancer-monitoring blood test. It analyzes cell-free DNA (cfDNA) fragments in the bloodstream to assess tumor burden and treatment response. This fragmentome-based liquid biopsy offers a non-invasive, cost-effective alternative to traditional methods, requiring minimal plasma and providing results within two weeks.

What Are Latest Mergers And Acquisitions In The Tumor Blood Testing Market?

In August 2025, Exact Sciences Corp., a US-based diagnostics and biotechnology company, acquired the rights to a blood-based colon cancer screening test from Freenome Holdings Inc. for an undisclosed amount. Through this acquisition, Exact Sciences Corp aims to strengthen its position in the early cancer detection market and expand its technological capabilities by incorporating Freenome Holdings, Inc.’s advanced multiomics and AI-driven blood testing platform. Freenome Holdings Inc. is a US-based biotechnology company focused on developing blood tests to detect cancer early.

Regional Outlook

North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Tumor Blood Testing Market?

The tumor blood testing market consists of revenues earned by entities by providing services such as liquid biopsy testing services, early cancer detection services, clinical trial support services, genetic mutation profiling services, and cancer biomarker screening services. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor blood testing market also includes sales of exosome isolation kits, immunoassay kits, microfluidic devices, epigenetic assay kits, and protein biomarker panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.